Oura, Whoop: Wearables Plug Licensed Doctors Into the App

LONDON, Friday, June 12, 2026 — Oura and Whoop are putting licensed doctors inside their apps, converting two of the most-watched consumer wearables into front doors for clinical care. Oura confirmed that its integration with virtual care provider Counsel Health begins rolling out in Oura Labs on June 16, 2026 to eligible members in 43 U.S. states. Whoop, valued at $10.1 billion after a $575 million Series G in March, will launch on-demand video consultations with licensed clinicians in the U.S. this summer, the company said in a press release. The two moves, announced within weeks of each other, mark the wearable category's most aggressive attempt yet to monetize biometrics through billable virtual care.

Key Takeaways

• The Counsel experience will begin rolling out in Oura Labs on June 16, 2026, to eligible Oura Members in 43 U.S. states.
• Whoop, which has over 2.5 million users globally, closed a $575 million funding round in March that raised the company's valuation to $10.1 billion.
• WHOOP announced plans to introduce live, on-demand video consultations with a licensed clinician in the United States this summer, according to the company.
• Oura has sold more than 5.5 million rings cumulatively since 2015 (with over half in the prior year), reported over $500 million in 2024 revenue, and projected reaching $1 billion in sales in 2025, according to the company.
• The new features follow Whoop's Series G funding round, which was one of 12 mega-deals that helped drive digital health funding to $4.0 billion across 110 deals in the first quarter of 2026, according to Rock Health.

Context & Analysis

The wearable industry spent a decade collecting biometric data with limited paths into clinical workflows. That gap is now the strategic prize. Oura and Whoop recently announced they'll make it possible for users to connect virtually with doctors directly from their apps, a move that could represent the first step in the long-awaited adoption of consumer health data by traditional clinical care.

Oura's path runs through Counsel Health, an AI-powered virtual care platform. Counsel physicians can view Oura data and health context within their clinical workflow, including biometric trends in sleep, cardiovascular, and reproductive health — visibility that can help physicians triage faster and make more informed decisions without needing to ask about a patient's entire health history. Whoop is pairing its clinician network with EHR integration from HealthEx. WHOOP will now support Electronic Health Record syncing, and members will be able to securely access clinical history including diagnoses, medications, and procedures directly within the app.

The competitive trigger is unmistakable. Whoop made its announcement one day after Google unveiled the Fitbit Air ($99) and its Gemini Health Coach subscription ($9.99/month). Where Google is leaning into AI-generated guidance, Whoop is explicitly offering licensed clinicians — a meaningful regulatory distinction.

Related: Future of AI in Wearables Market by 2030

Competitive Landscape

Whoop's pitch is that data context changes the doctor's appointment. Unlike traditional healthcare experiences that rely on brief, episodic snapshots, these consultations begin with a comprehensive understanding of the member's health, powered by months of continuous data and, when available, bloodwork and medical history. Backers include Mayo Clinic and Abbott, lending institutional credibility to a category historically dismissed as wellness.

Oura is pushing the same logic with subscription economics behind it. These services are available for an additional fee on top of the $5.99 monthly subscription all Oura users pay. Counsel Health's CEO Muthu Alagappan told the Boston Globe that Oura is interesting because it provides signals on blood pressure, oxygen, heart rate, and when users may be about to get sick — and that data can now be combined with actionability.

For deeper context, see our Wearables analysis: "Wearables Enter Clinical Phase: Smart Rings, CGMs and AI Glasses Deliver Breakthroughs in Q4".

The skeptics are louder than the marketing. The Food and Drug Administration has only authorized a handful of wearable features for clinical use, and the evidence base for using wearable data to inform medical care is nascent. Widespread use by clinicians will take considerably more work. Neither Oura nor Whoop has submitted its blood pressure features to the FDA for marketing authorization.

Additional coverage: Enterprise Wearables Move From Pilots to Core Infrastructure

Additional coverage: Frontline Work Goes Hands-Free as Microsoft, Meta, Zebra Trigger December Wearables Push

What It Means

For Enterprise Buyers

Self-insured employers and benefits platforms now have a credible path to plug wearable data into a billable clinician interaction without standing up a new vendor. Insurers should note that Oura is already wired into payer workflows: Hale points to Oura's new partnership with Essence Health, an insurer and provider for Medicare Advantage patients — if the ring detects possible sleep apnea, it alerts Essence Health's AI system, which follows up with diagnostic questions and next steps for treatment. Analysts expect HR teams may be asked about wearable-linked virtual care as a benefits SKU within 12 months.

For Investors

The subscription thesis just got a clinical revenue line. The announcement follows Oura's May 21, 2026 filing of a confidential draft S-1 registration statement with the SEC for a potential IPO, according to public reporting. Telehealth-only operators could face a flanking threat from device companies that already own the customer relationship and the data, analysts suggest. Pricing discipline is the swing variable — Whoop has not disclosed consultation pricing, and how it lands against Google's $9.99/month Gemini coach will shape attach rates.

Related: Temple & Zomato Founder Deepinder Goyal Target Brain Wearables Market 2026

Forward Outlook

Oura's Counsel rollout begins June 16, 2026, with state-by-state expansion tied to telemedicine licensing. Whoop's clinician access is expected to go live in the U.S. this summer, with pricing disclosed at launch. The next regulatory milestone is FDA clearance documentation for blood pressure features — Bloomfield said Oura is in the final stages of putting together documentation on the blood pressure feature and that it will be available imminently. International expansion timing remains undefined.

For deeper context, see our related analysis: "Wearables innovation: health-grade sensors, smart rings, and new revenue".

For deeper context, see our AI analysis: "Meta & Thinking Machines Signal AI Talent Shift 2026".

Related: Wearables Enter Clinical Phase: Smart Rings, CGMs and AI Glasses Deliver Breakthroughs in Q4

Additional coverage: How Wearables Is Driving Enterprise Value in 2026, According to Apple, Samsung and Gartner

Sources include company disclosures, regulatory filings, analyst reports, and industry briefings.

Related Coverage

• More Wearables Analysis
• Latest Technology News

Analysis based on company announcements, investor disclosures, regulatory filings, Reuters, Bloomberg, Financial Times, CNBC, SEC documentation, and publicly available market data as of publication.